open access
Characteristics of COVID-19 in pediatric patients with hematological malignancies
Affiliations- Department of Pediatrics N2, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
- Western Ukrainian Specialized Children’s Medical Centre, Lviv, Ukraine
- Department of Pediatrics and Neonatology FPGE, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
- Department of Pediatric Infectious Diseases, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
open access
Abstract
Introduction: As more data is collected, hematologists will be able to gain more insight into the impact of coronavirus disease 2019 (COVID-19) on pediatric patients with hematological malignancies.
Material and methods: We analysed 21 cases of COVID-19 in pediatric patients with onco-hematological diseases treated in the Western Ukrainian Pediatric Medical Center from March 2020 through May 2021. The majority of patients (71.4%) were diagnosed with acute lymphoblastic leukemia. All patients from the analyzed cohort had an asymptomatic, mild or moderate course of coronavirus-19 infection. The most common symptoms of COVID-19 were fever, cough, gastrointestinal symptoms, and dermatitis. Severe severe acute respiratory syndrome coronavirus 2 increased the risk of liver toxicity and venous thrombosis.
Results and conclusion: Our analysis showed that pediatric patients with hematological malignancies need the same treatment approach for COVID-19 as for other infective complications.
Abstract
Introduction: As more data is collected, hematologists will be able to gain more insight into the impact of coronavirus disease 2019 (COVID-19) on pediatric patients with hematological malignancies.
Material and methods: We analysed 21 cases of COVID-19 in pediatric patients with onco-hematological diseases treated in the Western Ukrainian Pediatric Medical Center from March 2020 through May 2021. The majority of patients (71.4%) were diagnosed with acute lymphoblastic leukemia. All patients from the analyzed cohort had an asymptomatic, mild or moderate course of coronavirus-19 infection. The most common symptoms of COVID-19 were fever, cough, gastrointestinal symptoms, and dermatitis. Severe severe acute respiratory syndrome coronavirus 2 increased the risk of liver toxicity and venous thrombosis.
Results and conclusion: Our analysis showed that pediatric patients with hematological malignancies need the same treatment approach for COVID-19 as for other infective complications.
Keywords
COVID-19, haematological malignancies, immunosuppression, paediatric patients
About this articleTitle
Characteristics of COVID-19 in pediatric patients with hematological malignancies
Journal
Issue
Article type
Original research article
Pages
273-276
Published online
2022-07-25
Page views
3585
Article views/downloads
204
DOI
Bibliographic record
Acta Haematol Pol 2022;53(4):273-276.
Keywords
COVID-19
haematological malignancies
immunosuppression
paediatric patients
Authors
Olga Troyanovska
Olga Dorosh
Halyna Lytvyn
Iryna Tsymbalyuk
Oxana Vorobel
Olena Stepanyuk
Hrystyna Bodak
Olena Kozlova
Mariya Stasiv
Nata Basiv
References (13)- Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. N Engl J Med. 2020; 382(17): 1663–1665.
- André N, Rouger-Gaudichon J, Brethon B, et al. COVID-19 in pediatric oncology from French pediatric oncology and hematology centers: High risk of severe forms? Pediatr Blood Cancer. 2020; 67(7): e28392.
- Mercolini F, Cesaro S. COVID-19 in children and adolescents: characteristics and specificities in immunocompetent and oncohematological patients. Mediterr J Hematol Infect Dis. 2022; 14(1): e2022009.
- Ragab D, Salah Eldin H, Taeimah M, et al. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020; 11: 1446.
- Cron RQ, Caricchio R, Chatham WW. Calming the cytokine storm in COVID-19. Nature Medicine. 2021; 27(10): 1674–1675.
- Yasuhara J, Watanabe K, Takagi H, et al. COVID-19 and multisystem inflammatory syndrome in children: a systematic review and meta-analysis. Pediatr Pulmonol. 2021; 56(5): 837–848.
- Schoot TS, Kerckhoffs APM, Hilbrands LB, et al. Immunosuppressive drugs and COVID-19: a review. Front Pharmacol. 2020; 11: 1333.
- Valencia-Sanchez C, Wingerchuk DM. A fine balance: immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19. Mult Scler Relat Disord. 2020; 42: 102182.
- Hrusak O, Kalina T, Wolf J, et al. Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment. Eur J Cancer. 2020; 132: 11–16.
- Hammad M, Shalaby L, Sidhom I, et al. Management and outcome of coronavirus disease 2019 (COVID-19) in pediatric cancer patients: a single centre experience from a developing country. Clin Lymphoma Myeloma Leuk. 2021; 21(11): e853–e864.
- Millen GC, Arnold R, Cazier JB, et al. Severity of COVID-19 in children with cancer: report from the United Kingdom Paediatric Coronavirus Cancer Monitoring Project. Br J Cancer. 2021; 124(4): 754–759.
- Diorio C, McNerney KO, Lambert M, et al. Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. Blood Adv. 2020; 4(23): 6051–6063.
- Taub JW, Ge Y, Xavier AC. COVID-19 and childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020; 67(7): e28400.